Emre Yucel
Newbury College
13 Papers
35 Citations
Emre Yucel is an academic researcher from Newbury College. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 10 publications. Previous affiliations of Emre Yucel include University of Texas at Austin & University of Texas MD Anderson Cancer Center.
Chat about Author
Papers
The symptom burden of treatment-naive patients with head and neck cancer.
Ehab Y. Hanna,Tito R. Mendoza,David I. Rosenthal,G. Brandon Gunn,Pamela Sehra,Emre Yucel,Charles S. Cleeland +6 more
TL;DR: Knowledge of disease‐related (treatment‐naive) symptom status would aid in the evaluation of the symptomatic benefit or burden of HNC therapies.
Strategic leadership in global business organizations: building trust and social capital
Michael A. Hitt,Barbara W. Keats,Emre Yucel +2 more
- 10 Apr 2003
TL;DR: In this paper, the authors show that when employees trust leaders, they are more likely to be committed to the organization's goals, willing to develop firm-specific knowledge and likely to exercise creativity.
32
Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale
Tito R. Mendoza,Xin Shelley Wang,Loretta A. Williams,Qiuling Shi,Elisabeth G. Vichaya,Patrick M. Dougherty,Sheeba K. Thomas,Emre Yucel,Christel C. Bastida,Jeanie F. Woodruff,Charles S. Cleeland +10 more
TL;DR: It is suggested that the nonpainful components of neuropathy may be more disabling than the pain component during cancer treatment, and the development of a neuropathy assessment scale that follows regulatory guidance for patient-reported outcomes is detailed.
29
Adverse drug reactions due to drug–drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method
TL;DR: The safety of PPI use with respect to DDIs is critically evaluated with a meta-review of systematic reviews published between 1978 and 2015, assessing the evidence by their reliability, repeatability, transparency, and objectivity.
25
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases.
TL;DR: A historical overview of the use of patient-reported outcomes and symptom assessment in solid-tumor and hematological drug development is provided, and recommendations about methodological issues in the monitoring of symptoms in the drug development process inHematological clinical trials are offered.